#obesity-drugs

[ follow ]
#novo-nordisk #weight-loss #ozempic #mergers--acquisitions #drug-pricing #bankruptcy #alzheimers-disease
Medicine
fromwww.theguardian.com
2 days ago

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer's trials

Oral semaglutide failed to slow Alzheimer's progression in two large trials, prompting a sharp share price drop for Novo Nordisk.
#ozempic
more#ozempic
Business
fromFortune
2 weeks ago

Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune

Pfizer will acquire development-stage obesity drugmaker Metsera for up to $86.25 per share, outbidding Novo Nordisk amid antitrust concerns.
fromwww.mediaite.com
2 weeks ago

MSNBC's Jen Psaki Roasts Trump for 'Nodding Off' in Oval

And when any White House experiences a humiliating defeat. And believe me, I've been part of those, the instinct is often most of the time to change the subject. I mean, roll out a new policy, hold a big event, make any announcement of any kind, basically to get people to talk about anything other than the absolute shellacking that you just took at the polls.
US politics
fromwww.npr.org
2 weeks ago

White House strikes deals for lower prices on obesity drugs

"We believe these deals, within two years based on our health improvements, we will be budget neutral,"
Public health
Business
fromMedCity News
3 weeks ago

Pfizer Lawsuits Allege Novo Nordisk's Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News

Pfizer secured regulatory approval for its $4.9B Metsera acquisition, but competing Novo Nordisk bid and related lawsuits may determine if and when the transaction closes.
Medicine
fromwww.theguardian.com
3 weeks ago

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

Novo Nordisk launched a $9bn unsolicited bid to acquire Metsera, directly challenging Pfizer's existing takeover offer amid competition for obesity-drug assets.
Healthcare
fromNature
4 months ago

Obesity drugs made in China could power next wave of treatments

Ecnoglutide is a promising next-generation obesity drug developed in China, showing significant advantages over placebo in weight loss.
US news
fromwww.npr.org
5 months ago

A new chapter for online sales of obesity drug alternatives tests legal limits

Chris Spears launched OrderlyMeds to provide compounded obesity drug alternatives after struggling to find prescribed medication.
#bankruptcy
fromwww.cbc.ca
6 months ago
Wellness

WeightWatchers files for bankruptcy after weight-loss drugs capsized industry | CBC News

WW International has filed for Chapter 11 bankruptcy to reduce its debt due to competition from new obesity medications.
fromNew York Post
6 months ago
Wellness

WeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs

WW International has filed for Chapter 11 bankruptcy due to rising competition from obesity drugs that undermined its traditional business model.
Wellness
fromNew York Post
6 months ago

WeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs

WW International has filed for Chapter 11 bankruptcy due to rising competition from obesity drugs that undermined its traditional business model.
more#bankruptcy
[ Load more ]